Rocket Pharmaceuticals — Third Quarter 2026 Earnings Summary

Rocket Pharmaceuticals reported a net loss of $49.2 million for the third quarter of 2026, with cash, cash equivalents, and investments totaling $279.4 million as of September 30, 2026. The company received FDA alignment to complete its pivotal Phase 2 trial of RP-A501 for Danon disease, with dosing expected to finish by mid-2027. Additionally, dosing has begun in the Phase 1 trial for RP-A701 targeting BAG3-associated dilated cardiomyopathy, and the commercial product KRESLADI achieved readiness with activated treatment centers on October 1, 2026.